Key result
In patients with rheumatic mitral stenosis and severe pulmonary arterial hypertension, a 24-hour dobutamine infusion significantly reduced mean right ventricular systolic pressure from 82 mmHg to 60 mmHg.
Why the study?
Does dobutamine improve haemodynamic parameters in patients with pulmonary hypertension secondary to mitral stenosis?
Observational (n=15)
No
Does dobutamine improve haemodynamic parameters in patients with pulmonary hypertension secondary to mitral stenosis?
Dobutamine improves cardiac output and decreases pulmonary vascular resistance in patients with pulmonary hypertension secondary to mitral stenosis.
Answers are grounded in this paper and cite their sources.
May support acute RVSP reduction with dobutamine in rheumatic MS with severe PAH; hypothesis-generating and requires prospective confirmation before practice change.
Significant Pulmonary Arterial Hypertension (PAH) is a common complication of mitral stenosis. The synthetic sympathomimetic amine dobutamine is a potent 1 receptor agonist with some 2 and receptor agonistic properties. The net haemodynamic effects with dobutamine are a substantial increase in cardiac output with little or no change in arterial pressure and heart rate. Systemic and pulmonary vascular resistances decrease along with a modest decrease in pulmonary arterial wedge pressure.
No takes yet. Share an insight, caveat, or question.
Bastian et al. (2016) conducted an observational in Mitral Stenosis with Pulmonary Arterial Hypertension (n=15). Dobutamine vs. Baseline was evaluated on Right Ventricular Systolic Pressure (RVSP) (p=<0.001). In patients with rheumatic mitral stenosis and severe pulmonary arterial hypertension, a 24-hour dobutamine infusion significantly reduced mean right ventricular systolic pressure from 82 mmHg to 60 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: